Touchlight has developed the enzymatic means of DNA amplification that resolves the significant issues with plasmid DNA fermentation that currently constrain the commercialisation of DNA based therapeutics.

Touchlight’s enzymatic DNA amplification platform is proven to address every major limitation of plasmid DNA. Touchlight’s platform is high-yielding, high-fidelity, eliminates antibiotic resistance and is capable of multi gram-scale amplification of unstable sequences (e.g. secondary structure, homopolymers) using an inexpensive benchtop process lasting less than 2 weeks.

Touchlight has exploited the unique properties of its platform to develop differentiated therapeutic applications within AAV, lentivirus, mRNA, CRISPR and DNA vaccines, as well as non-therapeutic applications in the DNA nanomaterials field.